Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models

References

• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–1146.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States a policy statement from the American Heart Association. Circulation: Heart Failure. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Nichols M, Townsend N, Scarborough P, et al. European cardiovascular disease statistics 2012. Brussels, Belgium: European Heart Network; Sophia Antipolis: European Society of Cardiology; 2012.
   Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;2016(37):2129–2200.
   Web of Science ®Google Scholar
• American Heart Association. Classes of heart failure 2015 2015 Aug 28. Available from: http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp.
   Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail. 2012;14:803–869.
   PubMed Web of Science ®Google Scholar
• Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361–371.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Emergencies preparedness, response, “Early warning systems”, 2015 2015 Aug 31. Available from: http://www.who.int/csr/labepidemiology/projects/ewarn/en/.
   Google Scholar
• Anker SD, Koehler F, Abraham WT. Telemedicine and remote management of patients with heart failure. Lancet. 2011;378:731–739.
   PubMed Web of Science ®Google Scholar
• Suter P, Suter WN, Johnston D. Theory-based telehealth and patient empowerment. Popul Health Manag. 2011;14:87–92.
   PubMed Web of Science ®Google Scholar
• Klersy C, De Silvestri A, Gabutti G, et al. A meta-analysis of remote monitoring of heart failure patients. J Am Coll Cardiol. 2009;54:1683–1694.
   PubMed Web of Science ®Google Scholar
• Inglis SC, Clark RA, McAlister FA, et al. Which components of heart failure programmes are effective? A systematic review and meta‐analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review. Eur J Heart Fail. 2011;13:1028–1040.
   PubMed Web of Science ®Google Scholar
• Mejhert M, Kahan T, Persson H, et al. Limited long term effects of a management programme for heart failure. Heart. 2004;90:1010–1015.
   PubMed Web of Science ®Google Scholar
• Titler MG, Jensen GA, Dochterman JM, et al. Cost of hospital care for older adults with heart failure: medical, pharmaceutical, and nursing costs. Health Serv Res. 2008;43:635–655.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Mauskopf J, Paul J, Grant D, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13:277–288.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford; New York: Oxford University Press; 2005.
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value in Health. 2003;6:9–17.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in ecomomic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217–227.
   PubMed Web of Science ®Google Scholar
• Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36).
   Google Scholar
• Burri H, Sticherling C, Wright D, et al. Cost–consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. Europace. 2013;15:1601–1608.
   PubMed Web of Science ®Google Scholar
• Klersy C, De Silvestri A, Gabutti G, et al. Economic impact of remote patient monitoring: an integrated economic model derived from a meta‐analysis of randomized controlled trials in heart failure. Eur J Heart Fail. 2011;13:450–459.
   PubMed Web of Science ®Google Scholar
• Laramée P, Wonderling D, Swain S, et al. Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. Heart. 2013;99:267–271.
   PubMed Web of Science ®Google Scholar
• Miller G, Randolph S, Forkner E, et al. Long-term cost-effectiveness of disease management in systolic heart failure. Med Decis Making. 2009.
   PubMed Web of Science ®Google Scholar
• Moertl D, Steiner S, Coyle D, et al. Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care. 2013;29:3–11.
   PubMed Web of Science ®Google Scholar
• Morimoto T, Hayashino Y, Shimbo T, et al. Is B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol. 2004;96:177–181.
   PubMed Web of Science ®Google Scholar
• Pandor A, Thokala P, Gomersall T, et al. Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. Health Technol Assess. 2013;17(32).
   Google Scholar
• National Clinical Guideline Centre. Chronic heart failure: the management of chronic heart failure in adults in primary and secondary care. London: National Clinical Guideline Centre; 2010. Available from http://guidance.nice.org.uk/CG108/Guidance/pdf/English
   Google Scholar
• Galbreath AD, Krasuski RA, Smith B, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation. 2004;110:3518–3526.
   PubMed Web of Science ®Google Scholar
• Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med. 1994;154:1143–1149.
   PubMedGoogle Scholar
• Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999;83:890–896.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244–258.
   PubMed Web of Science ®Google Scholar
• Goeree R, Burke N, O’Reilly D, et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opinion®. 2007;23:671–682.
   PubMed Web of Science ®Google Scholar
• Angermann CE, Störk S, Gelbrich G, et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study. Circulation: Heart Failure. 2012;5:25–35. CIRCHEARTFAILURE. 111.962969.
   Web of Science ®Google Scholar
• Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. New England J Med. 2010;363:2301–2309.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol. 2005;45:1654–1664.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275–283.
   PubMed Web of Science ®Google Scholar
• Eddy D. Technology assessment: the role of mathematical modeling. In: Assessing medical technologies, editors. Committee for evaluating medical technologies in clinical use, Institute of Medicine. Washington, DC: National Academy Press, 1985. p. 144–160.
   Google Scholar
• Goehler A, Geisler BP, Manne JM, et al. Decision-analytic models to simulate health outcomes and costs in heart failure. Pharmacoeconomics. 2011;29:753–769.
   PubMed Web of Science ®Google Scholar
• Frederix GW, Afzali HHA, Dasbach EJ, et al. Development and use of disease-specific (reference) models for economic evaluations of health technologies: an overview of key issues and potential solutions. PharmacoEconomics. August 2015;33(8):777–781.
   Web of Science ®Google Scholar
• Handels RL, Wolfs CA, Aalten P, et al. Diagnosing Alzheimer’s disease: a systematic review of economic evaluations. Alzheimer’s & Dementia. 2014;10:225–237.
   PubMed Web of Science ®Google Scholar
• Getsios MD, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease. Pharmacoeconomics. 2010;28:411–427.
   PubMed Web of Science ®Google Scholar
• Van Gestel A, Severens JL, Webers CA, et al. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value in Health. 2010;13:358–367.
   PubMed Web of Science ®Google Scholar
• Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000;283:2158–2160.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11:80.
   PubMed Web of Science ®Google Scholar